Pan-European Research Reveals Majority of Osteoporosis Patients not Receiving Recommended Combination of Calcium and Vitamin D With Treatment

Geneva (ots/PRNewswire) -

- Study Highlights Underlying Reasons for why Patients areMissing Their Supplementation

GENEVA, September 15 /PRNewswire/ --

New research published today at the annual meeting of theAmerican Society for Bone and Mineral Research (ASBMR), Montréal,Canada, reveals that less than half (43%) of patients in Europe withosteoporosis are claiming to take both calcium and vitamin Dsupplementation with their osteoporosis treatment.(i) Maximum benefitin managing osteoporosis can be achieved with combination therapy ofan osteoporosis treatment (such as a bisphosphonate) with calcium andvitamin D supplementation, (ii) yet the majority of patients in thisresearch claim they do not follow this approach.

"Patients with a low intake of calcium and vitamin D may not bereceiving the full benefit of their osteoporosis treatment if they donot take enough supplementation", said Professor Steven Boonen MD,PhD, of Leuven University in Belgium and lead author of the abstractreporting the research results. "It is important that patients notonly take both their calcium and vitamin D supplements, but also toensure that they take them regularly".

The patient research was conducted amongst 383 women aged 50years and older who had been diagnosed and treated forpost-menopausal osteoporosis in France (n=97), Germany (n=98), Spain(n=94) and the UK (n=94). The aim of the study was to evaluatetreatment knowledge and behaviour in women receiving treatment fortheir osteoporosis with regard to their calcium and vitamin Dsupplementation.

Patients need help to take supplementation regularly

Even when patients do take some form of supplementation, up to30% claim they regularly miss a dose. An analysis of those patientswho declared they were regularly missing a supplement dose revealedthis was due either to the fact that they were not convinced of theimportance of supplementation, or that they did not receive adetailed explanation from their treating physician.(i) Patientresponses also showed that there is a need for some sort of aid, forexample, a tool or packaging that would help them take theirosteoporosis medication and supplementation.(i) This need for help issupported by patient preference data, which shows that over 70% ofpatients believe that providing a bisphosphonate with calcium andvitamin D in one box can help them take their supplements regularlyand correctly.(iii)

Some European countries are performing better than others

The research highlights interesting differences in attitudes tosupplementation across the four European countries. These studyresults showed that Spain generally proved to be a leader in terms ofpatient behaviour and knowledge about supplementation. For example,when looking at supplement use, 90% of patients in Spain claimed thatthey were taking some form of supplementation (calcium alone, vitaminD alone or calcium and vitamin D) with their osteoporosis treatment,compared to as few as 61% in the UK and 69% in France.(i) Similarly,patients in Spain claimed to discuss supplementation with theirphysician more regularly than in other countries - 51% compared to36% in Germany, 24% in France and 9% in the UK. (iv)

Patient trends in the UK highlighted areas for improvement. Aswell as being the lowest users of supplements and one of the leastlikely to recognise the importance of calcium and vitamin Dsupplementation, almost a third of UK patients claimed to have neverdiscussed supplementation with their physician.(iv)

When it came to adhering to supplements, women in France appearedto be the most disciplined out of the four countries, with only 13%claiming to regularly miss a dose of any supplement. This was incontrast to the UK, where almost one in three patients reportedregularly missing a supplement dose. (i)

"The disparities between countries in attitudes tosupplementation may be due to differences in cultures, nationalhealth policies or local disease awareness initiatives" said DoctorPatrice Fardellone, of CHU Amiens Hospital in France. "Whilst thisresearch has shown some positive results, there is still room forimprovement. It is vital that clinicians continue to educate theirpatients on the importance of supplements and encourage them to seesupplementation as part of complete osteoporosis treatment."


About the research

The aim of the patient research was to gain an understanding, ona pan-European basis, of the habits and attitudes of osteoporosispatients regarding supplementation with calcium or vitamin D orcalcium plus vitamin D with their osteoporosis treatment(bisphosphonate). The research was conducted by IPSOS Suisse SA.(i) Atotal of 383 women across four countries (France, Germany, Spain andthe UK) currently taking bisphosphonate treatment for osteoporosiswere interviewed. A mixed data collection methodology was used tosurvey the patients, including online panels (UK, Spain), face toface interviews (Germany) and mail panel (France).

Patients in Europe with osteoporosis claiming to take bothcalcium and vitamin D supplementation with their osteoporosistreatment were split across the four countries as follows:

- Spain - 43% - UK - 37% - Germany - 49% - France - 46%

Even when patients do take some form of supplementation, up to30% claim they regularly miss a dose (13% in France, 19% in Germany,30% in the U.K. and 27% in Spain).

Caveats - Claimed data: All data from the market research is 'claimed data' i.e. based on patient's testimonials on their habits and beliefs regarding supplementation and their consultation experience - Data collection: Different methodology was used to collect the data across the four countries (as shown above). This could cause some bias when comparing countries - Selected statements: European averages provided are based on results of selected statements from market research. Comparisons have been made using the general ranking, which provides an indication of which country is leading and require further refinement. The full results of the market research are available from Procter & Gamble - Cultural bias: There may be cultural differences in patient reporting, with some countries over-claiming and others under-claiming about their experiences - The total figures for all countries: These are based on a simple average of the various countries under study. This average is not weighted by country population or by other relevant factors

About osteoporosis

Osteoporosis is a skeletal disease that increases bone fragilityand susceptibility to fracture. Fracture is a devastating consequenceof osteoporosis and can occur at any site of the body. A 50-year-oldwoman has around a 40% lifetime risk of suffering a fracture fromosteoporosis.(v)

Currently, osteoporosis accounts for 1.6 million hip fracturesworldwide per year.(vi) Amongst those patients who suffer a hipfracture, approximately one in five will die within the followingyear,(vii),(viii) and 40 percent will be unable to walk independentlyone year later.(ix)

About Procter & Gamble (NYSE:PG)

Three billion times a day, P&G brands touch the lives of peoplearound the world. The company has one of the strongest portfolios oftrusted, quality, leadership brands, including Pampers(R), Tide(R),Ariel(R), Always(R), Whisper(R), Pantene(R), Mach3(R), Bounty(R),Dawn(R), Pringles(R), Folgers(R), Downy(R), Lenor(R), Iams(R),Crest(R), Oral-B(R), Actonel(R), Duracell(R), Intrinsa(R) Olay(R),Head & Shoulders(R), Wella, Gillette(R), and Braun. The P&G communityconsists of over 135,000 employees working in over 80 countriesworldwide. Please visit http://www.pg.com for the latest news andin-depth information about P&G and its brands.



(i) Boonen S, Fardellone P, Quesada J, et al. OP patients'behaviours and understanding of the importance of calcium and vitaminD supplementation. ASBMR (abstract) September 2008

(ii) Boonen, S et al. The need for clinical guidance in the useof calcium and vitamin D in the management of osteoporosis: aconsensus report. Osteoporosis International, 2004; 15:511-519

(iii) Fardellone P, et al. A new combination packaging forosteoporosis treatment; patient preference and expected adherence tothe therapy. Calcified Tissue International, 2007;80(supp 1):s143(P332-T)

(iv) Osteoporosis supplement co-prescribing versus recommendationcompliance study. IPSOS Suisse. December 2007. P&G data on file

(v) Melton LJ, et al. Perspective. How many women haveosteoporosis? J Bone Miner Res 1992; 7: 1005-1010

(vi) International Osteoporosis Foundation. Facts and statisticsabout osteoporosis and its impact.http://www.osteofound.org/press_centre/fact_sheet.html

(vii) Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-basedstudy of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-1005

(viii) Leibson CL, Tosteson AN, Gabriel SE, et al. Mortality,disability, and nursing home use for persons with and without hipfracture: a population-based study. J Am Geriatr Soc 2002; 50:1644-1650

(ix) Magaziner J, Simonsick EM, Kashner TM, et al. Predictors offunctional recovery one year following hospital discharge for hipfracture: a prospective study. J Gerontol 1990; 45: M101-M107

Julia O'Brien, Ketchum, P: +44(0)78907-11-037, julia.o'brien@ketchum.com .

ots Originaltext: Procter & GambleIm Internet recherchierbar: http://www.presseportal.de

Contact:Julia O'Brien, Ketchum, P: +44(0)78907-11-037, julia.o'brien@ketchum.com .

Procter & Gamble

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Pan-European Research Reveals Majority of Osteoporosis Patients not Receiving Recommended Combination of Calcium and Vitamin D With Treatment